Naslov
The overview of immunostimulating activities of potential vaccine adjuvant - peptidoglycan monomer

Autori
Habjanec, L ; Halassy, B ; Frkanec, R ; Tomašić, J.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS - MVADS 2009 / - , 2009

Skup
MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS - MVADS 2009

Mjesto i datum
Beč, Austrija, 28.10.2009. - 30.10.2009

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
peptidoglycan monomer; adjuvant activity

Sažetak
Peptidoglycan monomer (PGM) is natural compound originating from Brevibacterium divaricatum cell wall peptidoglycan. It is water-soluble, non-pyrogenic, non-immunogenic and non-toxic compound with well defined chemical structure: GlcNAc-MurNAc-L-Ala-D-isoGln-mesoDpm(εNH2)-D-Ala-D-Ala. PGM exhibits versatile biological, namely antitumor, antimetastatic, immunorestorative and immunostimulating activities in different experimental models1. In our previous studies adjuvant activity of PGM has been well demonstrated. Studies were mostly carried out in mouse model with protein antigen ovalbumin. PGM enhanced production of total IgGs specific for OVA, as well as IgG1, Ig2a and IgG2b isotypes of IgG. In terms of cellular immune response, PGM increased lymph nodes cellularity from OVA-immunised mice and stimulated both in vitro proliferation of OVA-specific cells isolated from draining lymph nodes of immunised mice as well as their IFN-γ and IL-4 production2. Finally, the ratio of IgG1/IgG2a, used as an indication of induction of Th1/Th2-type of immune response, demonstrated the more pronounced effect of PGM toward Th2-biased immune response3. Due to fast enzymatic degradation, PGM has shorter immunostimulating action in vivo. However, its adjuvanticity can be further exploited and prolonged in combination with depot-acting adjuvants and delivery systems, such as oil-based adjuvants and liposomes, respectively. Addition of PGM to Incomplete Seppic adjuvants, ISA720 or ISA206, gave rise to more potent adjuvant formulations4, 5. PGM incorporated into liposomes induced stronger immune response also6. Further, PGM's adjuvanticity was compared with the adjuvanticity of structurally related muramyl dipeptide (MDP) and of Complete Freund's Adjuvant (CFA), the golden standard of adjuvant action. PGM showed similar adjuvanticity as MDP, hence both of them were significantly weaker adjuvants in comparison to very potent CFA. While both PGM and MDP shifted the immune response towards Th2-bias, CFA significantly lead the immune response towards Th1. Following these results and other examples, we will present and discuss in detail the overview of so far investigated immunostimmulating activities of PGM, as promising candidate for human and veterinary vaccines. 1Halassy B et al. In: Current Studies of Biotechnology, Vol IV – Immuno-Modulatory Drugs. Croatian Society of Biotechnology and Medicinska Naklada, Zagreb, 2005. pp. 137-43. 2Halassy Špoljar B et al. Vaccine 2002 ; 20:3543-50. 3Habjanec et al. Int Immunopharmacol 2008 ; 8:717-24. 4Halassy et al. Vaccine 2007 ; 25:3475-81 5Habjanec et al. Vet Immunol Immunopathol 2008 ; 12:232-40. 6Habjanec et al. J Liposome Res 2006 ; 16:1-16

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Temeljne medicinske znanosti, Biotehnologija

POVEZANOST RADA